Nanjing Pharmaceutical Group Company Limited engages in the distribution of pharmaceuticals, medical devices, and health products in China. It also involved in...
NPC released its performance for the first three quarters, with a net profit attributable to the parent company of 402 million yuan, a year-on-year decrease of 9.03%
NPC: Completed the repurchase of 17,999,900 shares
NPC: Will repay the principal and interest of 500 million yuan in ultra-short-term financing bonds
NPC: The cumulative conversion amount of Nanjing Pharmaceutical's convertible bonds is 66,000 yuan
NPC disclosed the progress of its centralized bidding repurchase of shares, having repurchased shares worth 80.2576 million yuan
Brief News: BAIYUNSHAN PH spent 750 million to acquire a 10% stake in NPC